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ABSTRACT
Patient assessment of disease activity in rheumatoid
arthritis (RA) may be useful in clinical practice, offering a
patient-friendly, location independent, and a time-efficient
and cost-efficient means of monitoring the disease. The
objective of this study was to identify patient-reported
outcome measures (PROMs) to assess disease activity in
RA and to evaluate the measurement properties of these
measures. Systematic literature searches were performed
in the PubMed and EMBASE databases to identify articles
reporting on clinimetric development or evaluation of
PROM-based instruments to monitor disease activity in
patients with RA. 2 reviewers independently selected
articles for review and assessed their methodological
quality based on the Consensus-based Standards for the
selection of health Measurement Instruments (COSMIN)
recommendations. A total of 424 abstracts were retrieved
for review. Of these abstracts, 56 were selected for
reviewing the full article and 34 articles, presenting 17
different PROMs, were finally included. Identified were:
Rheumatoid Arthritis Disease Activity Index (RADAI),
RADAI-5, Patient-based Disease Activity Score (PDAS)
I & II, Patient-derived Disease Activity Score with 28-joint
counts (Pt-DAS28), Patient-derived Simplified Disease
Activity Index (Pt-SDAI), Global Arthritis Score (GAS),
Patient Activity Score (PAS) I & II, Routine Assessment
of Patient Index Data (RAPID) 2–5, Patient Reported
Outcome-index (PRO-index) continuous (C) & majority
(M), Patient Reported Outcome CLinical ARthritis Activity
(PRO-CLARA). The quality of reports varied from poor to
good. Typically 5 out of 10 clinimetric domains were
covered in the validations of the different instruments.
The quality and extent of clinimetric validation varied
among PROMs of RA disease activity. The Pt-DAS28,
RADAI, RADAI-5 and RAPID 3 had the strongest and
most extensive validation. The measurement properties
least reported and in need of more evidence were:
reliability, measurement error, cross-cultural validity and
interpretability of measures.
INTRODUCTION
Traditionally, the monitoring of rheumatoid
arthritis (RA) in clinical trials and treat to
target strategies has been based on indices,
such as the Disease Activity Score (DAS),
Disease Activity Score with 28-Joint Counts
(DAS28), Clinical Disease Activity Index
(CDAI) or Simpliﬁed Disease Activity Index
(SDAI), involving formal joint counts per-
formed by trained professionals.1–3 Formal
joint counts, though valued for their informa-
tion, have been criticised for their use in daily
practice because of their time-consuming
Summary points
What is already known about this subject?
▸ Over the past years many Patient Reported
Outcome Measures (PROMs) have been devel-
oped to measure disease activity in Rheumatoid
Arthritis (RA), though information on these mea-
sures has been spread over numerous reports.
What does this study add?
▸ This study provides an overview of: available
PROMs to measure disease activity in RA, which
measurement properties have been assessed
and the level of evidence of validation efforts.
▸ Of all patient-reported outcome measures in this
review, Patient-derived Disease Activity Score
with 28-joint counts (Pt-DAS28), Rheumatoid
Arthritis Disease Activity Index (RADAI), RADAI-
5 and Routine Assessment of Patient Index Data
(RAPID) 3 had the strongest and most extensive
validation.
▸ The measurement properties least reported and
in need of more evidence are: reliability, meas-
urement error, cross-cultural validity and inter-
pretability of measures.
How might this impact on clinical practice?
▸ Physicians should be cautious when interpreting
patient-reported outcome measures for disease
activity and when comparing results of these
instruments across different countries.
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nature. With an increasing focus on patient-centred care,
rising costs in healthcare and accompanying decreases in
resources, patient-reported outcome measures (PROMs)
might offer a patient-friendly, location independent, and
time-efﬁcient and cost-efﬁcient means of monitoring
chronic diseases such as RA. PROM research in rheumatol-
ogy spans over 30 years, during which period various mea-
sures have been developed.4–8 These cover a broad
spectrum of health domains, reﬂecting useful information
from patients’ perspectives on the effectiveness of therap-
ies tested in clinical trials. The Health Assessment
Questionnaire Disability Index (HAQ), Rheumatoid
Arthritis Disease Activity Index (RADAI) and Routine
Assessment of Patient Index Data (RAPID) are well-known
examples of PROMs for RA that are used in trials as well as
in practice.2 5 6 Recently, though, other patient-reported
measures reﬂecting their ‘physician-based’ counterparts,
such as the Patient-derived Disease Activity Score with 28-
joint counts (Pt-DAS28) or Patient-derived Simpliﬁed
Disease Activity Index (Pt-SDAI), have also been devel-
oped.9–13 Until now, information about the measurement
properties of all these patient-reported disease activity
measures has been spread over numerous reports, hinder-
ing the comparison and choice of PROMs to monitor RA
disease activity.
In order to understand how we can make good use of
PROMs in daily practice, the ﬁrst step needed is to have
an overview of instruments suited to this task. Second,
the level of evidence for the various measurement prop-
erties of each PROM has to be determined in order to
make recommendations for clinical use. The objective of
this study was therefore to identify PROMs to assess
disease activity in RA and to evaluate their measurement
properties.
METHODS
Consensus-based Standards for the selection of health
Measurement Instruments (COSMIN http://www.
cosmin.nl) were applied in this systematic review.14–18
The ﬁrst step in the methodology recommended by
COSMIN is the development of a search strategy. This
strategy is a combination of ﬁve elements: a construct
search, a population search, an instrument search, a vali-
dated PubMed ﬁlter for measurement properties and an
exclusion ﬁlter.19 To retrieve as many PROM-based
instruments as possible, a search strategy was devel-
oped with the emphasis on sensitivity rather than spe-
ciﬁcity. PubMed and EMBASE were searched to
identify articles published between January 1994 and
May 2014. Studies eligible for inclusion in the search
results met the following criteria: English language,
published in an international peer-reviewed journal, an
adult RA population, a focus on clinimetric properties
of PROM-based (without a formal professional joint
count) instruments aimed at capturing disease activity
or focused on the association of PROM-based instru-
ments and disease activity measures. The focus on
PROMs speciﬁcally addressing disease activity, rather
than PROMs measuring other consequences of disease,
was chosen in order to collect a comparable set of
measures with respect to construct validity. The search
strategy was reﬁned with MeSH terms, keywords and
free-text words, until a test-set of 11 target publications
covering different PROM-based instruments was fully
covered.9 10 12 13 20–26 A full speciﬁcation of the
search strategies is presented in online supplementary
appendices I and II.
The second step of the review process involved inde-
pendent evaluation by two assessors (WK and JH) of
abstracts found by the search strategies. The selection
criteria were as follows:
Inclusion criterion:
The article describes psychometric/clinimetric develop-
ment or evaluation of a PROM-based instrument,
without a formal joint count, for assessing disease activity
in RA.
Exclusion criteria:
1. The article describes the above speciﬁcally for a
juvenile population.
2. The article describes the above speciﬁcally for a popu-
lation other than RA.
3. The article only describes results already presented in
earlier articles.
Any discordance in abstract selection was discussed in
a consensus meeting. Two assessors (MJdJ and JH) then
read the full text of the remaining articles as a ﬁnal
check of eligibility.
In the third step of the review, the methodological
quality of each included study was checked by two asses-
sors (MJdJ and JH) independently using COSMIN
checklists with a four-point rating scale ranging from
poor to excellent.18 Each measurement property, out of
a possible 10, was scored in a separate box containing
5–18 items referring to quality aspects for the respective
measurement property (eg, sample size, description of
missing items or statistical method used). The guidance
given to rate each item of the reported measurement
properties was followed and any existing discordance in
scores between the assessors was relieved in a second
consensus meeting. As recommended, a ﬁnal overall
rating for each measurement property, described in
each study, was determined by taking the lowest rating of
any item in the respective box. Additionally, the second
lowest score was reported to give insight into the possi-
bility of a single low score in a respective category deter-
mining the total score.
Finally, the study characteristics and clinimetric data
were extracted from the included studies (see table 1
and online supplementary appendix III).27–30 For the
interpretation of statistical measures being reported in
studies, several suggestions have been stated. According
to Nunnally and Bernstein,31 a Cronbach’s α of 0.8 is
sufﬁcient for research purposes and a value of 0.9 is
recommended in case individual decisions are based on
speciﬁc test scores. As a rule of thumb, Hinkle et al have
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proposed the following categorisation for correlational
measures: 0.1–0.29 no or negligible correlation, 0.30–
0.49 low correlation, 0.50–0.69 moderate correlation,
0.70–0.89 high correlation and 0.9–1.0 very strong cor-
relation.32 For Cohen’s κ as a measure of agreement,
several different categorisations have been proposed,
though can largely be regarded as: <0.4 poor, 0.4–0.6
fair/moderate, 0.60–0.80 substantial/good, 0.80–1.00
excellent/almost perfect.33–36 According to Swets, area
under the curve (AUC) values from 0.5 to 0.7 represent
poor accuracy, those from 0.7 to 0.9 are moderate and
those above 0.9 represent high accuracy.37 For the
overall overview of measurement properties across the
included studies (table 2), the following values were con-
sidered as positive indicators of the respective measure-
ment property: Cronbach’s α ≥0.80, correlation
coefﬁcients ≥0.60, Cohen’s κ ≥0.60, AUCs ≥0.70. Since
there is a lack of guidance for categorisation of the mag-
nitude of measurement error, we considered the meas-
urement error to be positive if it was on par or smaller
than similar physician-reported measures (eg, DAS28 or
SDAI) that were reported in the same study. The overall
quality and consistency of evidence for the measurement
properties of each instrument (evaluated over multiple
Table 1 Characteristics of the study population of included studies
Study Size Age Female (%) RF+ (%) Disease duration DAS28 at baseline
Blanchais et al38 26 56.6 (9.5) NR NR 16.6 (10) y NR
Bossert et al39 200 57 (11.5) 75.5 78 13 (8.3) y 3.61 (1.43)
Castréjon et al40 39 56.8 (13.9) 90 NR 3.5 (NR) y NR
Castréjon et al41 720 48.2 (12.4) 76.2 NR 4.8 (2.9–7.0)* m 5.1 (1.3)
Choy et al9 322 60.3 (23–87)† 76 81 9.13 (0–48)† y NR
Fransen et al42 92 52 (13) 83 87 9 (4–14)* y NR
Fransen et al20 584 59 (12) 72 69 8 (3–15)* y 4.3 (1.4)
Fujiwara et al43 250 59.3 (14) 78.4 NR 10.35 (9.83) y NR
Harrington44 185 63 (22–88)† NR NR 18 (2–51)‡ y NR
Heegaard et al45 30 60 (15) 77 70 15 (6)y 3.5 (1.0)§
Houssien et al10 100 57.7 (12.2) 78 NR 11.5 (8.3) y 4.24 (1.3)
Janta et al11 69 60.12 (13.16) 76.8 NR 11.9 (8.6) y 2.55 (1.08)
Kavanaugh et al12 218 54.3 (21–88)† 81.7 NR 8.5 (NR) y 5.4 (1.3)
229 54.7 (19–82)† 76.9 7.2 (NR) y 5.0 (1.3)§
Leeb et al21 169 57 (19–78)† 79.8 50 7.2 (0.2–46)† y 3.51 (0.28–6.67)†
Leeb et al22 108 59.5 (24–87)‡ 77.7 54 NR 2.95 (0.43–6.24)‡
Pincus46 63 58.5 (19.7)* ref ref 3.5 (8.8)* y ref
30 54.6 (20.9)* 2.9 (8.9)* y
Pincus et al23 557 ref ref ref ref 6.82 (NR)/6.83(NR)
278 6.89 (NR)/6.88(NR)
Pincus et al47 1384 ref ref ref ref ref
Pincus et al48 982 ref ref ref ref ref
Pincus et al49 557 ref ref ref ref ref
227
Pincus et al50 Ref ref ref ref ref ref
Pincus et al51 285 57.4 (14.6) 73 NR 9.7 (9.0) y 3.4 (1.7)
Pincus et al52 200 53.4 (16.2) 81 NR 11.6 (10.8) y 3.7 (1.5)
Riazzoli et al13 47 50 (13) 79 86 9.4 (8.6) y 5.4 (1.2)
Rintelen et al24 392 61 (20–87)‡ 82.1 59.4 62 (3.545)‡ m 3.26 (0.49–8.09)‡
Rintelen et al53 705 62.7 (13.4) 75.9 54.4 97.3 (98.0) m 3.31 (1.37)
Salaffi et al54 191 56.6 (12.2) 82.7 NR 5.1 (5.5) y 6.02 (1.15)
Salaffi et al55 196 56.7 (12.1) 83.1 78 5.1 (5.9) y 3.94 (2.03)
247 58.1 (11.2) 80.1 76 6.2 (6.6) y
Singh et al56 200 42.2 (NR) 83 NR 4.9 (NR) y 5.2 (1.6)
Stucki et al57 55 60.0 (14.6) 62 NR 5.1 (1.3–10.7)* y NR
Sullivan et al58 740 57 (13.7) 83 63.8 14.3 (12.3) y 4.05 (1.5)§
Uhlig et al59 28 61.1 (6.2) 64 64 16.6 (10.4) y 3.12 (1.27)
Veehof et al25 191 54.5 (13.3) 71 NR 7.0 (3–17)* y 5.42 (1.07)
Wolfe et al26 9078 62.2 (12.6) 78.2 NR 16.2 (10.9) y NR
*Median(IQR): Values are mean (standard deviation) unless otherwise indicated.
†Mean (range).
‡Median (range).
§DAS28-CRP.
CRP, C-reactive protein; DAS28, Disease Activity Score with 28-Joint Counts; m, months; NR, not reported; ref, reference to results in earlier
publication; RF+, rheumatoid factor positive; y, years.
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Table 2 Overall levels of evidence of measurement properties per instrument across all included studies
Instrument
Internal
consistency Reliability
Measurement
error
Content
validity
Structural
validity
Cross-cultural
validity
Hypothesis
testing
Criterion
validity Responsiveness Interpretability
RADAI10 20 21 25 42 54 55 57–59 ++
0.84–0.91 α
?
0.92 ICC
?
14.9%maxSDD
? ++
1 factor
? +++ −−
0.48–0.83s
++
0.77 AUCresponder
?
RADAI-521 22 24 39 53 ++
0.91–0.92 α
? ? ? ++
1 factor
? ++ ++
0.62–0.66s
–
0.589s/0.295κ
?
PDAS I9 –
0.5 α
+
0.76–0.88
? ? ? ? + +
0.89s
? ?
PDAS II9 –
0.4 α
+
0.76–0.88
? ? ? ? + +
0.76s
? ?
Pt-DAS2810–13 45 ? +
0.92p
+
23.2%meanSSD
? ? ? ++ ++
0.73–0.94p
± ?
Pt-SDAI11 45 ? +
0.90p
+
59.9%meanSSD
? ? ? + ++
0.87s 0.93p
? ?
PAS I26 54 ? ? ? ? ? ? + ? +
0.79 AUCresponder
?
PAS II26 ? ? ? ? ? ? + ? ? ?
RAPID 223 ? ? ? ? ? ? ? ? ? ?
RAPID 322 38–41 43 46 48–52
54–56 59
++
0.87 α
?
0.90
?
14.8%maxSDD
? ++
1 factor
? ++ ++
0.64–0.91s
±
0.80 AUCresponder
0.43–0.53 wκ
?
RAPID 4 PtJC23 38 51 ? ? ? ? ? ? ? ++
0.65s
? ?
RAPID 4 MDJC23 ? ? ? ? ? ? ? ? ? ?
RAPID 523 51 58 ? ? ? ? ? ? ? ++
0.69–0.71s
+
0.70s
?
PRO-CLARA54 55 +
0.89 α
? ? ? +
1 factor
? + +
0.84s
+
0.82 AUCresponder
?
PRO-Index C/M47 ? ? ? ? ? ? ? ? + ?
GAS44 58 ? ? ? ? ? ? ? −−
0.54s
–
0.50s
?
+, positive result; −, negative result (for explanation of the categorisation of the levels, see table 3); %maxSDD, SDD as percentage of maximum value of outcome; %meanSDD, SDD as
percentage of mean value of the outcome; α, Cronbach’s α; τ, Kendall’s τ; AUCflare, area under the curve for patients with flare versus no flare; AUCresponder, area under the curve for patients
responding to therapy versus not responding; GAS, Global Arthritis Score; ICC, interclass correlation coefficient; MDJC, Medical Doctor Joint Count; p, Pearson’s correlation coefficient; PAS,
Patient Activity Score; PDAS, Patient-based Disease Activity Score; PRO-Index C/M, Patient Reported Outcome-index continuous (C) & majority (M); Pt-DAS28, Patient-derived Disease Activity
Score with 28-joint counts; PRO-CLARA, Patient Reported Outcome CLinical ARthritis Activity; PtJC, Patient Joint Count; Pt-SDAI, Patient-derived Simplified Disease Activity Index; RADAI,
Rheumatoid Arthritis Disease Activity Index; RAPID, Routine Assessment of Patient Index Data; s, Spearman’s correlation coefficient; SDD, smallest detectable difference; wκ, Weighted Kappa.
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studies shown in online supplementary appendix III)
was summarised using a method originally proposed by
the Cochrane Back review group and that has been used
by others since (table 3).20–23 Depending on the pres-
ence of either one or more studies of fair, good or excel-
lent methodological quality, and the consistency of
ﬁndings across studies, the level of overall evidence
ranges from unknown to strong (table 3).
RESULTS
The search strategy resulted in 358 articles in PubMed
and 275 articles in EMBASE. The two search strategies
had a 32% overlap, resulting in 424 articles to be reviewed
(ﬁgure 1). Independent assessment of the abstracts
resulted in 94% concordance and consensus was reached
after discussing the remaining abstracts. Discordance was
mostly due to discussion if the article was aimed at validat-
ing PROM-based instruments intended to measure
disease activity. After consensus, 56 abstracts were
included for full review and 368 were excluded.
Of the 56 articles that were retrieved for full-text
review, 22 were excluded. Reasons for exclusion were as
follows: the reported instrument was not speciﬁcally
developed to assess disease activity; the reported instru-
ment was not PROM based; the article reviewed results
of earlier publications; the report did not focus on a
clinimetric evaluation or the report did not provide sub-
group analyses for the RA subpopulation.
The 34 articles included for full review described
the following instruments: Pt-SDAI, Patient-derived
Disease Activity Score with 28-joint counts (Pt-DAS28),
Patient-Based Disease Activity (PDAS) I, PDAS II,
RADAI, RADAI-5, Patient Activity Score (PAS) I, PAS
II, RAPID 3, Routine Assessment of Patient Index Data
4-Patient Joint Count (RAPID 4-PtJC), Routine
Assessment of Patient Index Data 4 Medical Doctor
Joint Count (RAPID 4-MDJC), RAPID 5, Patient
Reported Outcome-index (PRO-index) majority (M),
continuous (C), Patient Reported Outcome CLinical
ARthritis Activity (PRO-CLARA).9–13 20–26 38–59 An over-
view of the basic study characteristics is given in table 1.
Most reports focused on 2 or 3 out of 10 possible meas-
urement properties (see online supplementary appendix
III). Aspects of validity and responsiveness were evaluated
most frequently, whereas aspects of interpretation, cross-
cultural validity, content validity, measurement error and
reliability were seldom or not investigated. The quality of
individual studies ranged from poor to excellent. Most
noted reasons for poor scores were: not reporting
missing items, not reporting how missing items were
dealt with and poor choice of statistical measures.
Levels of evidence, over multiple studies, for each of
the 17 instruments are shown in table 2. Overall, most
instruments had limited or moderate levels of evidence
for 3–5, out of a possible 10, measurement properties.
The four instruments with the most extensive validations
and strongest levels of evidence were: Pt-DAS28, RADAI,
RADAI-5 and RAPID 3.
Table 3 Levels of evidence for the overall quality of
measurement properties per instrument across all included
studies20–23
Level Rating Criteria
Strong +++ or
−−−
Consistent findings in multiple
studies of good methodological
quality OR in one study of
excellent methodological quality
Moderate ++ or
−−
Consistent findings in multiple
studies of fair methodological
quality OR in one study of good
methodological quality
Limited + or – One study of fair methodological
quality
Conflicting ± Conflicting findings
Unknown ? No studies or only studies of poor
methodological quality
+, positive result; –, negative result.
Figure 1 Search results PubMed/EMBASE, overlap,
exclusion based on abstract review, exclusion based on full
review.
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DISCUSSION
In this study, PROM-based instruments for disease activ-
ity in RA were identiﬁed and their measurement proper-
ties were systematically reviewed based on the COSMIN
method.14–19 27 29 60 There is a large body of research
related to patient-reported outcomes with inconsistent
usage of terms describing outcome measures that are
patient reported and terms describing different aspects
of clinimetric validation. A lot of work has been carried
out validating several PROM-based instruments to
capture disease activity, though none of the identiﬁed
instruments have good quality validation studies covering
all clinimetric domains (table 2). All the information
gathered in this review will be taken up in the European
League Against Rheumatism (EULAR) Outcomes
Measures Library (OML; http://oml.eular.org/) in
order to create an openly accessible database of
PROM-based measures, which can be updated with new
information as it becomes available.61
The ﬁrst part of this review involved identifying
reports which described the clinimetric/psychometric
evaluation of PROM-based instruments to assess disease
activity in RA. The two search strategies (PubMed and
EMBASE) resulted in a substantial amount of unique
candidate articles and 32% overlap in search hits (see
ﬁgure 1, online supplementary appendices I and II).
This demonstrates the value of not restricting search
efforts to only one major referencing database.
In the second review round, 56 reports were included
for full-text evaluation of PROM-based instruments and
their measurement properties. Most candidates did not
meet the inclusion criterion that the article described in
a clinimetric/psychometric evaluation of a PROM-based
instrument. This was to be expected as the search strat-
egies (see online supplementary appendices I and II)
were developed with a focus on sensitivity not speciﬁcity,
due to a lack of consistent terminology for describing
clinimetric evaluations and PROMs in the literature
until now.16 19 It is notable that the Rheumatoid
Arthritis Impact of Disease (RAID) instrument was not
selected for this systematic review. This decision was
made because this instrument was designed to capture
‘patients’ perception of the impact of the disease on
domains of health.62 This covers a broader construct of
health, including, for example, emotional well-being,
when compared with the more ‘biologically’ oriented
clinical indices of disease activity.63 Additionally, the
focus of the RAID is on the impact of disease, which can
be moderated by coping. These differences make the
RAID heterogeneous to the instruments speciﬁcally
focusing on RA disease activity, which this review was
aimed at, and therefore less comparable, especially with
regard to assessment of validity.
The third part of this review involved rating the level
of evidence for each measurement property reported in
the 34 articles selected in step 2. As recommended by
COSMIN, the level of evidence was determined by the
lowest score of all quality items for each measurement
property. Almost all articles failed to report the number
of missing items, or did not describe how missing data
were handled, reducing the quality rating of the evi-
dence (see online supplementary appendix III). In
order to adequately evaluate an instrument, it is import-
ant to know if certain items are often missing and why
this is so. The issue of failure to report missing data and
their handling is not restricted to clinimetric evaluations;
between 2006 and 2014, it has been reported as 1 of the
14 most frequently given review comments in the Annals
of Rheumatic Diseases.64 We encourage authors and jour-
nals to place more emphasis on clear reporting of the
occurrence and handling of missing data in the respect-
ive methods and results sections of the reports. Another
aspect that was not clearly reported was the measure-
ment model of the instrument. The COSMIN guide dif-
ferentiates between reﬂective and formative models.65
Reﬂective models consist of items which are a manifest-
ation of the same underlying construct. Also known as
effect indicators, these items are expected to be highly
correlated and interchangeable. Formative models
consist of items that together form the construct. These
items do not need to be correlated and internal consist-
ency is therefore not relevant. Judging by the content of
most instruments, these are probably based on formative
models. Since there was no clear description of the
measurement models, we scored internal consistency
measurement properties as suggested by COSMIN guide-
lines. It should, however, be noted that these scores are
most likely not relevant to the reported instruments and
should therefore not be taken into account when
judging its clinimetric quality. Of further note, some
authors chose to refer to earlier reports for the descrip-
tion of the study population, which we would not
advise.23 47–50 This hampers readers from adequately
judging reported instruments, as the diversity of the
study population can severely impact the evaluation of
measurement properties.
In the fourth and ﬁnal step of the review, all the avail-
able evidence of each instrument was compiled into
table 2. It can be seen that the result of using the classiﬁ-
cation method proposed in table 3, that it is not neces-
sarily the case that the PROMs which have been most
published on, such as RADAI or RAPID 3, are thereby
automatically the ‘best’ scores with regard to evidence.
This is due to the quality of each individual validation
study or the presence of conﬂicting ﬁndings across
studies. Furthermore, explicit judgement on which are
the ‘best’ scores is not given because that is reliant on
the purpose for which the instruments are to be used.
Some physicians might want to trade off ease of use
against accuracy of an instrument, while others might
not. Therefore, an overview with regard to the evidence
available of these measures is provided and the choice
of instruments is up to the reader/user, for they will be
the best judges given the intended use.
To the best of our knowledge, this is the ﬁrst systematic
review based on the COSMIN method for PROM-based
6 Hendrikx J, et al. RMD Open 2016;2:e000202. doi:10.1136/rmdopen-2015-000202
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instruments assessing disease activity in patients with RA.
It adds to earlier reviews of physician-based/professional-
based instruments for disease activity assessment.2 6 We
limited the review to studies published in the past
20 years, because these instruments are the most likely to
be relevant to current clinical trials and daily practice.
The aim of the search strategy was to focus on sensitivity.
The search used a validated PubMed ﬁlter in conjunction
with many free-text terms and identiﬁed all 11 test-set
articles plus an additional 23 other relevant validation
studies. This strengthens our belief that the search strat-
egy was indeed sensitive; however, it is still possible that
some validation studies were not found due to the high
heterogeneity of terms used in the literature. To ensure
the uptake of evidence concerning clinimetric evaluation
of PROMs, we recommend that authors pay close atten-
tion to choosing appropriate keywords in the title,
abstract and keyword section, and that they make use of
consistent terminology suggested by COSMIN.16 As part
of the EULAR OML strategy, authors of the identiﬁed
instruments will be contacted and encouraged to provide
any evidence that might have been missed by the search
strategy to further enhance sensitivity. The OML will be
periodically updated with new evidence by reﬁning and
rerunning the search strategies (see online supplemen-
tary appendices I and II).
Clinical implications of this systematic review can be
deduced from table 2. It is clear that until now the most
effort has gone into the measurement properties con-
cerning validity aspects (hypothesis testing, criterion val-
idity, responsiveness). Other clinimetric domains such as
reliability and interpretability are in need of more evi-
dence. If, for instance, the measurement error or
minimal important change is not well known, this
impedes the use of a measure. The clinical implication
of this is that without these measurement properties phy-
sicians cannot judge if differences in scores are due to
chance and if they are truly important to their patients.
In addition to this, evaluations of cross-cultural validity
and direct comparison studies are needed in order to
facilitate comprehension of instrument scores across dif-
ferent studies and different countries. Without evidence
of formal validations of instruments in the language of
their choice, physicians should be cautious of using
instruments, comparing scores or generalising results of
clinical studies using instruments in languages other
than their patients’.
In conclusion, this systematic review of PROM-based
instruments identiﬁed 17 measures aimed at monitoring
disease activity in RA. The quality and extent of clini-
metric validation varied among reports. The measure-
ment properties least reported and in need of more
evidence were: reliability, measurement error, cross-
cultural validity and interpretability of measures. In
general, the Pt-DAS28, RADAI, RADAI-5 and RAPID 3
had the strongest and most extensive validation. We
hope this systematic review will aid professionals in the
choice of PROM-based tools for disease activity
assessment in RA. It is a ﬁrst step in enhancing standard-
isation and clinimetric evaluation of these measures for
disease activity in RA, and ultimately for supporting
their use in clinical trials and daily practice.
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